Formac Pharmaceuticals: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Formac Pharmaceuticals
Largest movements
- Cash +€1,625
up €1,625 (+772%), from €211 to €1,835
mainly Net result for the year (+€1,622) and Receivables within one year (+€2)
- Profit (loss) carried forward +€1,622
up €1,622 (0.0%), from -€6.9m to -€6.9m
- Gross operating margin -€142,979
down €142,979 (-98.2%), from €145,623 to €2,644
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €489 | €2,112 | +€1,622 | +331% |
| Fixed assets | 21/28 | €0 | - | = | |
| Intangible fixed assets | 21 | €0 | - | = | |
| Current assets | 29/58 | €489 | €2,112 | +€1,622 | +331% |
| Amounts receivable within one year | 40/41 | €279 | €276 | -€2 | -0.9% |
| Trade receivables | 40 | €20 | €0 | -€20 | -100% |
| Other amounts receivable | 41 | €259 | €276 | +€18 | +6.8% |
| Cash at bank and in hand | 54/58 | €211 | €1,835 | +€1,625 | +772% |
| Total equity and liabilities | 10/49 | €489 | €2,112 | +€1,622 | +331% |
| Equity | 10/15 | €489 | €2,112 | +€1,622 | +331% |
| Contributions | 10/11 | €6,887,603 | €6,887,603 | = | 0.0% |
| Capital | 10 | €6,887,603 | €6,887,603 | = | 0.0% |
| Issued capital | 100 | €6,887,603 | €6,887,603 | = | 0.0% |
| Reserves | 13 | €449 | €449 | = | 0.0% |
| Tax-exempt reserves | 132 | €449 | €449 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€6,887,562 | -€6,885,940 | +€1,622 | 0.0% |
| Amounts payable | 17/49 | €0 | - | = | |
| Amounts payable after more than one year | 17 | €0 | - | = | |
| Financial debts | 170/4 | €0 | - | = | |
| Amounts payable within one year | 42/48 | €0 | - | = | |
| Trade debts | 44 | €0 | - | = | |
| Suppliers | 440/4 | €0 | - | = | |
| Other amounts payable | 47/48 | €0 | - | = | |
| Accrued charges and deferred income | 492/3 | €0 | - | = | |
| Non-recurring operating income | 76A | €149,264 | €4,500 | -€144,764 | -97.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €0 | - | = | |
| Other operating charges | 640/8 | €0 | €829 | +€829 | |
| Non-recurring operating charges | 66A | €174,299 | €0 | -€174,299 | -100% |
| Gross operating margin | 9900 | €145,623 | €2,644 | -€142,979 | -98.2% |
| Operating profit (loss) | 9901 | -€28,676 | €1,815 | +€30,491 | |
| Financial income | 75/76B | €0 | - | = | |
| Recurring financial income | 75 | €0 | - | = | |
| Financial charges | 65/66B | €206 | €193 | -€13 | -6.4% |
| Recurring financial charges | 65 | €206 | €193 | -€13 | -6.4% |
| Profit (loss) for the period before taxes | 9903 | -€28,882 | €1,622 | +€30,504 | |
| Profit (loss) for the period | 9904 | -€28,882 | €1,622 | +€30,504 | |
| Profit (loss) for the period to be appropriated | 9905 | -€28,882 | €1,622 | +€30,504 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.